Mirati Therapeutics (MRTX) Financial Analysis & Valuation | Quarter Chart
Mirati Therapeutics (MRTX)
MRTXPrice: $58.7
Fair Value: 🔒
🔒score
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSC... more
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address... more
Description
Shares
| Market Cap | $4.12B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Charles M. Baum |
| IPO Date | 2013-07-15 | CAGR | 0.03% |
| Employees | 587 | Website | www.mirati.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MRTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $2.62B | P/E Ratio | -4.82 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 331.11 | P/B Ratio | 3.31 |
| P/CF Ratio | -5.79 | P/FCF Ratio | -7.16 |
| EPS | $-12.18 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 223.63% | Gross Margin | 0.95% |
| Operating Margin | -61.08% | Profit Margin | -59.57% |
| ROE | -0.62% | ROA | -0.62% |
| ROCE | -0.73% | Current Ratio | 6.96 |
| Quick Ratio | 6.94 | Cash Ratio | 1.48 |
| Debt/Equity | 0.05 | Interest Coverage | — |
| Altman Z Score | 8.55 | Piotroski Score | 3 |